RxDoctor Payments Data

Jonathan Tripp, DO

Family Medicine · Twin Falls, IDNPI 1558491936

Payments from drug & device makers

$1,829in general payments, 2019–2025

Across 104 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$547
  • AstraZeneca$502
  • Lilly USA, LLC$162
  • Novo Nordisk$157
  • Exact Sciences$103
  • Merck$73
  • plus $287 from 11 others

What the payments were for

  • Food & beverage$1,829100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,829 in reported general payments places this provider in the 80th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$90,075
Medicare patients
183
Services billed
1,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$26,423
OzempicSemaglutide26$24,074
FarxigaDapagliflozin Propanediol35$22,319
JardianceEmpagliflozin20$17,375
XareltoRivaroxaban17$11,542
Levothyroxine Sodium143$1,730
Atorvastatin Calcium93$994
Losartan Potassium129$917
Duloxetine Hcl34$869
Celecoxib17$754
Tamsulosin Hcl60$636
Amlodipine Besylate107$603
Pantoprazole Sodium44$578
Rosuvastatin Calcium41$570
Omeprazole57$540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$26,42331 claims
Novo NordiskOzempic$157$24,07426 claims
AstraZenecaFarxiga$502$22,31935 claims
Boehringer IngelheimJardiance$17$17,37520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 803 family medicine providers in Idaho.

Other family medicine in Twin Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →